Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.00), EUR0.72 worse than the analyst estimate of (EUR0.28). Revenue for the quarter came in at EUR213.63 million versus the consensus estimate of EUR213.17 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.